Published by
@ShahidNShah
@ShahidNShah
June 20 to June 22, 2023
Boston Park Plaza, 50 Park Plaza, Boston, Massachusetts, 02116, United States
With 9 preclinical candidates actively being studied and 21 clinical trials taking place, the Adenosine landscape is bubbling with activity! No stone is left unturned as CD73, CD39, A1AR, A2AR, and Interior adenosine pathways are exploited. The field is poised to leap on the momentum from clinical success at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit.
Returning as the premier event devoted to improving the efficacy of drugs that target the adenosine pathway, overcoming obstacles related to resistance and immunosuppression, and accelerating the translation of therapeutics into the clinic.
Join experts in adenosine, immune checkpoint, tumor microenvironment, immune-oncology, and second-generation IO as they learn how combination medicines might improve the effectiveness and potency of treatment.
With more speakers, content, and networking opportunities than ever before, don't miss this opportunity to overcome these obstacles and exploit the adenosine pathway's therapeutic and commercial potential.
Read on adenosine-pathway-immunotherapy.com
Continue reading at adenosine-pathway-immunotherapy.com
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Nov 21, 2024 at 6:20am